These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9498179)

  • 41. Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.
    Altamura AC; Caldiroli A; Buoli M
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):649-60. PubMed ID: 25728382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 43. Topiramate and panic attacks in patients with borderline personality disorder.
    Clivaz E; Chauvet I; Zullino D; Niquille M; Maris S; Cicotti A; Lazignac C; Damsa C
    Pharmacopsychiatry; 2008 Mar; 41(2):79. PubMed ID: 18311689
    [No Abstract]   [Full Text] [Related]  

  • 44. Gabapentin in somatoform and panic disorder.
    Joos AA; Zeeck A
    J Clin Psychopharmacol; 2013 Feb; 33(1):140-2. PubMed ID: 23288241
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy studies of alprazolam in panic disorder.
    Spiegel DA
    Psychopharmacol Bull; 1998; 34(2):191-5. PubMed ID: 9640999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sensitization of catastrophic cognition in cognitive-behavioral therapy for panic disorder.
    Noda Y; Nakano Y; Lee K; Ogawa S; Kinoshita Y; Funayama T; Watanabe N; Chen J; Noguchi Y; Kataoka M; Suzuki M; Furukawa TA
    BMC Psychiatry; 2007 Dec; 7():70. PubMed ID: 18067686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Newer antidepressants and panic disorder: a meta-analysis.
    Andrisano C; Chiesa A; Serretti A
    Int Clin Psychopharmacol; 2013 Jan; 28(1):33-45. PubMed ID: 23111544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-situation safety behaviors among patients with panic disorder: descriptive and correlational study.
    Funayama T; Furukawa TA; Nakano Y; Noda Y; Ogawa S; Watanabe N; Chen J; Noguchi Y
    Psychiatry Clin Neurosci; 2013 Jul; 67(5):332-9. PubMed ID: 23773318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?
    Wiborg IM; Dahl AA
    Arch Gen Psychiatry; 1996 Aug; 53(8):689-94. PubMed ID: 8694682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The assessment and treatment of refractory anxiety.
    Hollander E; Cohen LJ
    J Clin Psychiatry; 1994 Feb; 55 Suppl():27-31. PubMed ID: 7915712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New insights into panic attacks.
    Yeragani VK
    J Psychiatr Res; 1995; 29(5):343-5. PubMed ID: 8748059
    [No Abstract]   [Full Text] [Related]  

  • 52. Medication management with panic disorder in the exercise state: some prescribing guidelines.
    Benjamin AB
    CNS Spectr; 2007 Mar; 12(3):184. PubMed ID: 17427322
    [No Abstract]   [Full Text] [Related]  

  • 53. [Compulsive buying: psychological and biological treatment].
    Lejoyeux M
    Encephale; 2007 Nov; 33(Pt 3):873-5. PubMed ID: 18402361
    [No Abstract]   [Full Text] [Related]  

  • 54. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
    Fux M; Taub M; Zohar J
    Acta Psychiatr Scand; 1993 Oct; 88(4):235-7. PubMed ID: 8256637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The abrupt discontinuation of fluvoxamine in patients with panic disorder.
    Black DW; Wesner R; Gabel J
    J Clin Psychiatry; 1993 Apr; 54(4):146-9. PubMed ID: 8486592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
    Jaffe RJ; Juneja NS; Juneja NS; Jaffe RJ; Coffey BJ
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):488-490. PubMed ID: 30226805
    [No Abstract]   [Full Text] [Related]  

  • 57. Blocking the cycle of panic disorder. Ways to gain control of the fear of fear.
    Vanin JR; Vanin SK
    Postgrad Med; 1999 May; 105(5):141-6; quiz 205. PubMed ID: 10335325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
    Cowley DS; Adams JB; Pyke RE; Cook J; Zaccharias P; Wingerson D; Roy-Byrne PP
    Biol Psychiatry; 1996 Sep; 40(6):550-2. PubMed ID: 8879478
    [No Abstract]   [Full Text] [Related]  

  • 59. Optimizing Clozapine Benefit While Minimizing Adverse Effects with Concomitant Fluvoxamine Treatment in an Adolescent with Schizoaffective Disorder.
    Rice T; Friedman S; Tatum J; Weiss-Goldman N; Kufert Y; Coffey BJ
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):66-71. PubMed ID: 30681385
    [No Abstract]   [Full Text] [Related]  

  • 60. What can I do to help an older person who is experiencing anxiety?
    Peat C; McGeorge S
    Nurs Older People; 2012 Mar; 24(2):14. PubMed ID: 22474829
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.